ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1875

Hyoscine Butylbromide Inhibits Neutrophil Cell Death Induction by Cocaine-levamisole. a Proof of Concept for the Management of Vasculopathy Induced by Cocaine-Levamisole

Manuela Osorio1, Tulio Lopera1, Teresita Coneo2, Isabel Velásquez-Giraldo2, Ruben Vargas2, Adriana Lucía Vanegas-García3, Mauricio Rojas2, Gloria Vasquez4 and Carlos Muñoz-Vahos5, 1Universidad de Antioquia, Medellin, Colombia, 2Universidad de Antioquia, Medellín, Colombia, 3Division of rheumatology, Universidad de Antioquia – Hospital San Vicente Fundación, Medellín, Colombia, 4Division of rheumatology, Universidad de Antioquia, Medellin, Colombia, 5Hospital San Vicente Fundación, Medellín, Colombia

Meeting: ACR Convergence 2021

Keywords: cocaine, levamisol, levamisole-induced autoimmunity, muscarinic receptors, neutrophils

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 9, 2021

Title: Vasculitis – Non-ANCA-Associated & Related Disorders Poster II (1862–1888)

Session Type: Poster Session D

Session Time: 8:30AM-10:30AM

Background/Purpose: The Vasculopathy induced by Cocaine-Levamisole (VICOL) is a recently described vasculopathy characterized by the presence of tissue necrosis. One of the possible mechanisms associated with this disease is the presence of NETosis a type of cell neutrophil cell death. The content of Nets is involved in endothelial activation and could explain the clinical manifestations. The muscarinic receptors M3 could be activated by levamisole and induce Netosis, an event that triggers the inflammation associated with the disease.

Methods: Neutrophils from healthy controls were isolated on a density gradient Ficoll-Dextran 3%, and cell viability and purity were assessed by stain with PI, DIOC6, and CD45-PCy7 and CD33-PE, respectively. After that, the induction of NETosis was evaluated through treatment with 40µM of Cocaine and 20nM of Levamisole and a mix of two components (40µM and 20nM). Then, neutrophils were cultured in polystyrene test tubes for 6 hours. As a positive control, 10 nM PMA was used. The presence of cell death was established by stains with 2µM Sytox and 1µg/µl Hoechst using cytometry. The double-positive cells indicate the presence of cell death. For the evaluation of inhibition, 10 nM and 20 nM of Hyoscine Butylbromide were added to the cultures before the stimulus, and the presence of cell death was also evaluated by cytometry. Flow cytometer data was analyzed using FlowJo, and statistical analysis was performed using GraphPad Prism V.8.

Results: The induction of neutrophil cell death was observed in the presence of cocaine and levamisole. A mean of 2.52% (range 0.443-3.35) and 20.28% (8.02-44.7) of neutrophils suffer cell death in the presence of cocaine and levamisole, respectively. The mix of Cocaine-Levamisole increases the median of cell death by 67.43% (31.3-88.8). The PMA was used as a control and induce cell death of 17.96% (11.3- 25.6). The cell death inhibition was assessed in neutrophils treated with Cocaine-Levamisole in the presence of 10nM and 20nM Hyoscine Butylbromide. The percentage of inhibition observed was 59.15% (15.9-80.3) with 10 nM of inhibitor and 40.95% (4.9-79.4) with 20 nM of inhibitor. As negative control not treated- neutrophils were evaluated and showed a cell death induction of 5,86% (3.5-8.9).

Conclusion: These results show that Levamisole induces a higher proportion of cell death than Cocaine, the mix of Cocaine-Levamisole enhanced the percentage of cell death. Hyoscine Butylbromide can inhibit the cell death induced by Cocaine-Levamisole. This is the first evidence of the capacity of Hyoscine Butylbromide to inhibit this phenomenon. In this study, we used flow cytometry as a tool for the evaluation of cell death that suggests NETosis. However, this strategy of flow cytometry should be assessed with antibodies against molecules involved in NETosis. The evidence of this study could suggest the potential use of this medicament to reduce the clinical manifestations of VICOL.

Carmona-Rivera C, et al. A role for muscarinic receptors in neutrophil extracellular trap formation and levamisole-induced autoimmunity. JCI Insight. 2017 Feb 9;2(3):e89780.

Sponsored by ASOREUMA and Programa de Sostenibilidad Universidad de Antioquia

Figure 1: Hyoscine Butylbromide inhibits neutrophil cell death induction by cocaine-levamisole. Percentage of neutrophils cell death stimulated by PMA [10 nM], cocaine (C) [40 µM], levamisole (L) [20 nM] cocaine-levamisole (C-L) and non-stimulated cells (n=5). Inhibition of cell death by Hyoscine Butyl bromide (BBH) at 10nM and 20 nM induced by cocaine-levamisole (C-L+I) (n=5). ANOVA I and Bonferroni comparison of means was used to calculate the p-value. Error bars represent mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001.


Disclosures: M. Osorio, None; T. Lopera, None; T. Coneo, None; I. Velásquez-Giraldo, None; R. Vargas, None; A. Vanegas-García, None; M. Rojas, None; G. Vasquez, None; C. Muñoz-Vahos, None.

To cite this abstract in AMA style:

Osorio M, Lopera T, Coneo T, Velásquez-Giraldo I, Vargas R, Vanegas-García A, Rojas M, Vasquez G, Muñoz-Vahos C. Hyoscine Butylbromide Inhibits Neutrophil Cell Death Induction by Cocaine-levamisole. a Proof of Concept for the Management of Vasculopathy Induced by Cocaine-Levamisole [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/hyoscine-butylbromide-inhibits-neutrophil-cell-death-induction-by-cocaine-levamisole-a-proof-of-concept-for-the-management-of-vasculopathy-induced-by-cocaine-levamisole/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/hyoscine-butylbromide-inhibits-neutrophil-cell-death-induction-by-cocaine-levamisole-a-proof-of-concept-for-the-management-of-vasculopathy-induced-by-cocaine-levamisole/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology